Abstract: In some implementations, a method is performed by a device including a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, the method includes obtaining user movement information. In some implementations, the user movement information characterizes a first body pose of the user at a first time and a second body pose of the user at a second time. In some implementations, the method includes determining whether a transition from the first body pose to the second body pose satisfies an acceptability threshold. In some implementations, the method includes in response to determining that the transition from the first body pose to the second body pose satisfies the acceptability threshold, generating a sequence of movements for a synthesized reality (SR) representation of the user.

Abstract: In some implementations, a method is performed by a device including a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, the method includes obtaining user movement information. In some implementations, the user movement information characterizes a first body pose of the user at a first time and a second body pose of the user at a second time. In some implementations, the method includes determining whether a transition from the first body pose to the second body pose satisfies an acceptability threshold. In some implementations, the method includes in response to determining that the transition from the first body pose to the second body pose satisfies the acceptability threshold, generating a sequence of movements for a synthesized reality (SR) representation of the user.

Abstract: In some implementations, a method is performed by a device including a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, the method includes obtaining user movement information. In some implementations, the user movement information characterizes a first body pose of the user at a first time and a second body pose of the user at a second time. In some implementations, the method includes determining whether a transition from the first body pose to the second body pose satisfies an acceptability threshold. In some implementations, the method includes in response to determining that the transition from the first body pose to the second body pose satisfies the acceptability threshold, generating a sequence of movements for a synthesized reality (SR) representation of the user.

Abstract: Compositions of nucleic acid hybridization probes for detecting a nucleic acid target sequence and methods for their production are described. In one preferred embodiment, the nucleic acid hybridization probe includes a hybridization domain, an adaptor, a linker, and a signaling domain. The hybridization domain includes a nucleic acid sequence having complementarity to the nucleic acid target sequence. The adaptor is a nucleic acid sequence. The linker includes a moiety having at least one abasic site, such that the moiety blocks extension by an elongating polymerase on a nucleic acid template containing the moiety. The signaling domain comprises a nucleic acid having at least one label or a nucleic acid having at least one nucleic acid domain for binding at least one additional nucleic acid.

Abstract: Methods, compositions and kits for screening for the presence of Epidermal Growth Factor Receptor variant 3 (EGFR(v3)) in a sample are disclosed. The method comprises obtaining a sample containing a plurality of cells; hybridizing a set of chromosomal probes to the sample, wherein the set comprises an EGFR(v3)-probe and a probe to chromosome 7 different from an EGFR(v3)-probe; and visualizing the hybridization pattern of the set of chromosomal probes in the plurality of cells of the sample, wherein the presence of at least one copy of chromosome 7 lacking a hybridization signal of the EGFR(v3)-probe in at least one cell is indicative of the presence of the EGFR(v3) in the sample. The methods, compositions and kits are suitable for diagnosing the therapeutic outcome for treating a patient having a cancer with an anti-EGFR therapeutic agent and for screening a sample for a predisposition for forming an EGFR-associated cancer.

Abstract: Methods of screening a sample for a predisposition for forming an EGFR-associated cancer and the presence of EGFR (v3) contained therein are described. The methods include the steps of obtaining a sample containing a plurality of cells and hybridizing a first set of labeled chromosomal probes and a second set of labeled chromosomal probes to the sample. The first set of labeled chromosomal probes specific to chromosome 7, and the second set of labeled chromosomal probes is a labeled EGFR(v3)-probe. The first and second sets of labeled chromosomal probes include different labels to permit identification of the first and second sets of labeled chromosomal probes hybridized to the sample. The method includes calculating the number of signals of the first and second sets labeled chromosomal probes on an individual cell basis and determining a predisposition for forming an EGFR-associated cancer and the presence of EGFR (v3) contained therein based upon those calculations.

Abstract: Method and compositions for screening for the presence of Epidermal Growth Factor Receptor variant 3 (EGFR(v3)) in a sample are described. The method comprises obtaining a sample containing a plurality of cells; hybridizing a set of chromosomal probes to the sample, wherein the set comprises an EGFR(v3)-probe and a probe to chromosome 7 different from an EGFR(v3)-probe; and visualizing the hybridization pattern of the set of chromosomal probes in the plurality of cells of the sample, wherein the presence of at least one copy of chromosome 7 lacking a hybridization signal of the EGFR(v3)-probe in at least one cell is indicative of the presence of the EGFR(v3) in the sample. The method and compositions are suitable for diagnosing the therapeutic outcome for treating a patient having a cancer with an anti-EGFR therapeutic agent and for screening a sample for a predisposition for forming an EGFR-associated cancer.

Abstract: The present invention relates to rapid, sensitive methods for determining whether a subject is at risk of developing lung cancer or has lung cancer based on certain combinations or biomarkers or biomarkers and biometric parameters.

Abstract: Method and compositions for screening for the presence of Epidermal Growth Factor Receptor variant 3 (EGFR(v3)) in a sample are described. The method comprises obtaining a sample containing a plurality of cells; hybridizing a set of chromosomal probes to the sample, wherein the set comprises an EGFR(v3)-probe and a probe to chromosome 7 different from an EGFR(v3)-probe; and visualizing the hybridization pattern of the set of chromosomal probes in the plurality of cells of the sample, wherein the presence of at least one copy of chromosome 7 lacking a hybridization signal of the EGFR(v3)-probe in at least one cell is indicative of the presence of the EGFR(v3) in the sample. The method and compositions are suitable for diagnosing the therapeutic outcome for treating a patient having a cancer with an anti-EGFR therapeutic agent and for screening a sample for a predisposition for forming an EGFR-associated cancer.

Abstract: The present invention relates to rapid, sensitive methods for determining whether a subject is at risk of developing lung cancer or has lung cancer based on certain combinations or biomarkers or biomarkers and biometric parameters.

Abstract: The present invention relates to rapid, sensitive methods for determining whether a subject has or is at risk of developing lung cancer based on certain combinations of biomarkers, or biomarkers and biometric parameters. The methods consist of: a) quantifying in a test sample obtained from a subject, the amount of two or more biomarkers in a panel, the panel comprising at least one antibody and at least one antigen: b) comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison: c) combining the assigned score for each biomarker quantified in step b to obtain a total score for said subject: d) comparing the total score in step c with a predetermined total score and e) determining whether said subject has a risk of lung cancer based on the comparison in step d.

Abstract: Compositions of nucleic acid hybridization probes for detecting a nucleic acid target sequence and methods for their production are described. In one preferred embodiment, the nucleic acid hybridization probe includes a hybridization domain, an adaptor, a linker, and a signaling domain. The hybridization domain includes a nucleic acid sequence having complementarity to the nucleic acid target sequence. The adaptor is a nucleic acid sequence. The linker includes a moiety having at least one abasic site, such that the moiety blocks extension by an elongating polymerase on a nucleic acid template containing the moiety. The signaling domain comprises a nucleic acid having at least one label or a nucleic acid having at least one nucleic acid domain for binding at least one additional nucleic acid.

Abstract: The present invention relates to rapid, sensitive methods for determining whether a subject has or is at risk of developing lung cancer based on certain combinations of biomarkers, or biomarkers and biometric parameters. The methods consist of: a) quantifying in a test sample obtained from a subject, the amount of two or more biomarkers in a panel, the panel comprising at least one antibody and at least one antigen: b) comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison: c) combining the assigned score for each biomarker quantified in step b to obtain a total score for said subject: d) comparing the total score in step c with a predetermined total score and e) determining whether said subject has a risk of lung cancer based on the comparison in step d.

Abstract: Making a suspended or soluble macromolecular conjugate comprising binding a first macromolecule to a solid via a stable, disruptable bond, stably linking additional macromolecules, and releasing the macromolecular conjugate, as well as macromolecular conjugates prepared by the method.

Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as BS106 and transcribed from breast tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer. Also provided are antibodies which specifically bind to BS106-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BS106 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.

Abstract: The present invention relates to rapid, sensitive methods for determining whether a subject is at risk of developing lung cancer or has lung cancer based on certain combinations or biomarkers or biomarkers and biometric parameters.

Abstract: This invention relates generally to a multimeric polypeptide complex/antigen which may be utilized in detecting or diagnosing diseases of the uterus such as uterine cancer. Furthermore, the invention relates to methods and kits, for example, which utilize this antigen or an antibody thereto. The complex itself comprises at least one EU250 polypeptide and at least one polypeptide which may be a BU101 polypeptide and/or a TU104 polypeptide. The complex may further comprise other, as yet unknown, polypeptide sequences.

Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS190 and transcribed from prostate tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS190-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS190 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BL172 and transcribed from urinary tract tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the urinary tract, such as urinary tract cancer. Also provided are antibodies which specifically bind to BL172-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BL172 polypeptide, which molecules are useful for the therapeutic treatment of urinary tract diseases, tumors or metastases.